IVI’s research brief series, Value Blueprints, profiles learnings from the Open-Source Value Project to spark exploration among health economics and outcomes research community into advancing next-generation value assessment methods.
Patient Insights as the Foundation for Value
May 20, 2019
To ensure that the patient perspective guided the development of IVI’s open-source model for EGFR+ non-small cell lung cancer (NSCLC), IVI partnered with patients to conduct qualitative research on patient experiences with treatment. This brief summarizes the results of these interviews and focus groups with NSCLC patients and insights into what factors determine value from patients’ perspectives.
Exploring the Implications of the “Value of Hope”
May 20, 2019
There is increasing interest in augmenting cost-effectiveness analysis to include novel elements like the value of hope, but the implications for value assessment are unclear. Using the IVI-NSCLC model, this research brief illustrates the potential impacts of incorporating patient risk preferences in a hypothetical analysis and how accounting for patients’ attitudes towards risks in treatment outcomes affects value.
Enhancing Our Understanding of Long-Term Value: Insurance Value
July 25, 2019
New medical technologies can benefit not only patients, but also healthy people at risk of future illness. The “insurance value” of this decrease in physical risks of illness is an important element in understanding value at the broader population level, but methods for estimating and incorporating are nascent. This brief uses the IVI-RA model to illustrate the application of insurance value and explore potential implications.
The Impact of Structural Uncertainty on Cost-Effectiveness Estimates
September 3, 2019
Structural assumptions may impact model results, but this structural uncertainty is not generally measured or addressed in cost-effectiveness studies. In this research brief, we use the IVI-RA model to demonstrate how different structural assumptions lead to varying cost-effectiveness estimates. We then show why cost-effectiveness studies should explicitly incorporate and report effects of structural uncertainty to ensure that real-world decision-makers have complete information.
Aligning Value Assessment with Treatment in Chronic Disease
December 9, 2019
ICER’s recent assessment of JAK inhibitors for RA raises the question: Do conventional value assessments address the questions most relevant to real-world decisions about treatment pathways for chronic diseases? This issue brief discusses the limitations of conventional value assessment approaches in chronic diseases with sequential treatment options and points to new methods being developed by IVI.